Folia Health: The Home-Reported Outcomes Company

What is the status quo costing patients? Do clinicians and payers understand the unmet need? Download the guide to learn how to answer these critical questions.

Of launches that missed first-year revenue targets, 46% were due to an inadequate understanding of patient need. Get the guide to measure that need before launch.

How can we prove people feel better on our therapy? People report it, on Folia. Book a call to get started.

I'm cold and it's raining so it must be CONFERENCE SEASON! Next up - speaking at the 14th IMPACCT Real-World Evidence Summit in Boston on October 28, alongside the formidable Carmine Colavecchia, PharmD, PhD of argenx! We'll discuss recent developments in Patient-Focused Drug Development (PFDD) - specifically where traditional RWE sources fall flat, and how patient-generated evidence can fill the gap. Our premise for the conversation: if it doesn't matter to the patient, what are we measuring? At Folia, we collaborate with our participant partners to generate fit-for-purpose, home-reported evidence that helps our partners characterize burden and unmet need in their focus conditions, building the differentiation story for their therapies. Catch us at 2:30pm ET - register via the link in the comments! #IMPACCTBoston

Enjoyed a morning spent at Pfizer Innovation in Cambridge yesterday with biopharma leaders, discussing paths forward for high-impact implementation of digital tools for research & launching of therapies. This is a key area for directly relating drug development to what individual people need. As Brett Hauber said, which I resonated with deeply: "Are we measuring something that matters to patients?...What is the impact of this condition on your life, what would make it better, and how can we measure this? We often start with a measure first..but does it truly matter?" (Slide from Click Therapeutics, Inc.)

This past week, we registered a formal comment with the FDA in response to the proposed pilot program to use AI in early-stage clinical trials. In short - we maintained our position that AI output is only as good as the input. If you've spent any time in health informatics, you know that there's a lot of junk that passes for information. There is so much promise in accelerating the pace of life-changing therapies brought to people who need them - but to do this well, we need to make sure that we inform the models with context and patient-driven data that reflects whether people are actually feeling better in their everyday lives. Imagine - if we had that simple information for every drug - how easy this process could be! https://lnkd.in/gxDX9UDr